Navigation Links
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
Date:9/16/2009

t and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. O
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
4. Amgen to Present at the Barclays Capital Global Healthcare Conference
5. Amgen Announces Webcast of 2009 First Quarter Financial Results
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen Highlights Data to Be Presented at ASCO
10. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
11. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... 2014 Tbdress.com has recently announced ... on Nov. 28, 2014. The special offer will provide ladies ... is one of the world’s largest women’s dresses retailers, and ... People can enjoy great discounts on that day: Everything at ... delivery (for orders above $89). , People can use the ...
(Date:11/23/2014)... 2014 (HealthDay News) -- Close friends have more influence ... does, a new study says. "We,ve known ... an influence on individual alcohol use, but there are ... group and the friend group,s influence on those decisions," ... of Public Health, said in a university news release. ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... “BlackVue” was featured on NewsWatch as part of ... latest and coolest technology products available to consumers. Mallory ... the product review and shared with viewers how their ... car camera industry. , The need for in-car video ... find the one that’s right per consumer, especially considering ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... Patients with obstructive sleep apnea (OSA) who ... of continuous positive airway pressure (CPAP) relieves them of ... the October 15 issue of the Journal of Clinical ... The Sleep Center at Universitys Community Hospital in Tampa, ...
... published in the October 15 issue of the Journal ... Sleepiness Questionnaire (CASQ), a new self-completed instrument to measure ... by James C. Spilsbury, PhD, of the Division of ... a subsample of 411 adolescents between 11-17 years of ...
... France, October 15 Sanofi Pasteur, the,vaccines ... partnership,with Institut Pasteur to develop a vaccine ... will have access to antigens,identified by Institut ... for the most deadly malaria infections. Sanofi ...
... SEATTLE, October 15 - ,Real Women, Real ... Recognition and Treatment in Women Around the World ... (IASP) has,declared 2008 the Global Year Against Pain in ... pain on women and the need for more,effective care. ...
... leading cancer organizations shows cancer death rates decreased on ... nearly twice the annual decrease of 1.1 percent per ... in the Annual Report to the Nation on the ... and Alaska Natives published online October 15, 2007 ( ...
... One of the most distressing aspects of Alzheimer,s disease is ... beginning of an inevitable mental decline. Researchers at the Stanford ... is a step toward giving people an answer two to ... , The test identifies changes in a handful of proteins ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 3Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 2Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 3Health News:Annual report to the nation finds cancer death rate decline doubling 2Health News:Annual report to the nation finds cancer death rate decline doubling 3Health News:Annual report to the nation finds cancer death rate decline doubling 4Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 2Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 3Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 4
(Date:11/24/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced today that Sergio Traversa , chief ... MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December ... Luxe Sunset Bel Air Hotel, which is located at ... . The presentation is scheduled for ...
(Date:11/24/2014)... , Nov. 24, 2014  AiCure, an artificial ... technology to monitor medication ingestion, has announced the ... and intervene with patients receiving medication as maintenance ... overdoses from prescription opiates have quadrupled in the ... per year than heroin, cocaine and benzodiazepines combined. ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: